These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29048237)

  • 1. Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.
    Berdelou A; Borget I; Godbert Y; Nguyen T; Garcia ME; Chougnet CN; Ferru A; Buffet C; Chabre O; Huillard O; Leboulleux S; Schlumberger M
    Thyroid; 2018 Jan; 28(1):72-78. PubMed ID: 29048237
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
    Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution.
    Porcelli T; Luongo C; Sessa F; Klain M; Masone S; Troncone G; Bellevicine C; Schlumberger M; Salvatore D
    Endocrine; 2021 Aug; 73(2):358-366. PubMed ID: 33537956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
    Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
    N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.
    Balmelli C; Railic N; Siano M; Feuerlein K; Cathomas R; Cristina V; Güthner C; Zimmermann S; Weidner S; Pless M; Stenner F; Rothschild SI
    J Cancer; 2018; 9(2):250-255. PubMed ID: 29344270
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
    J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
    Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
    Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.
    Lorusso L; Pieruzzi L; Biagini A; Sabini E; Valerio L; Giani C; Passannanti P; Pontillo-Contillo B; Battaglia V; Mazzeo S; Molinaro E; Elisei R
    Onco Targets Ther; 2016; 9():6467-6477. PubMed ID: 27799794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
    Lorusso L; Newbold K
    Future Oncol; 2015; 11(12):1719-27. PubMed ID: 26075440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects.
    Hamidi S; Boucher A; Lemieux B; Rondeau G; Lebœuf R; Ste-Marie LG; Le XK; Mircescu H
    J Endocr Soc; 2022 Jun; 6(6):bvac048. PubMed ID: 35475024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma.
    Roque J; Nunes Silva T; Regala C; Rodrigues R; Leite V
    Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36852694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria.
    Rendl G; Sipos B; Becherer A; Sorko S; Trummer C; Raderer M; Hitzl W; Ardelt M; Gallowitsch HJ; Pirich C
    Int J Endocrinol; 2020; 2020():8834148. PubMed ID: 33312196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
    De Leo S; Di Stefano M; Persani L; Fugazzola L; Colombo C
    Endocrine; 2021 May; 72(2):462-469. PubMed ID: 32885329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study.
    Matsuyama C; Enokida T; Ueda Y; Suzuki S; Fujisawa T; Ito K; Okano S; Tahara M
    Front Oncol; 2023; 13():1139659. PubMed ID: 37886165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice.
    Nervo A; Gallo M; Samà MT; Felicetti F; Alfano M; Migliore E; Marchisio F; Berardelli R; Arvat E; Piovesan A
    Anticancer Res; 2018 Mar; 38(3):1643-1649. PubMed ID: 29491097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.